Literature DB >> 4021725

Oral administration and distribution of melatonin in human serum, saliva and urine.

O Vakkuri, J Leppäluoto, A Kauppila.   

Abstract

In order to evaluate for future physiological and pharmacological studies the extent to which orally administered melatonin is found in human serum and saliva and excreted into urine we measured serum, saliva and urine concentrations of melatonin by radioimmunoassay after oral administration of 100 mg melatonin. Elevated melatonin concentrations were observed with peak values of 435 nmol/l in serum and 241 nmol/l in saliva at 60 min. Elimination was monophasic following first-order kinetics. The half-lives for serum and saliva melatonin were 41 and 38 min, respectively. The results suggest that melatonin is passively secreted into saliva which reflects closely the changes in serum melatonin. Saliva sampling is thus useful in studies on peripheral melatonin both in physiological and experimental conditions. Urinary excretion of melatonin was 0.01 % of the amount of melatonin ingested. In high-performance liquid chromatography urine extracts were found to contain also a minor unknown immunoreactive component which we suggest to be some unknown metabolite of melatonin.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4021725     DOI: 10.1016/0024-3205(85)90412-6

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  16 in total

1.  Urinary metabolites and antioxidant products of exogenous melatonin in the mouse.

Authors:  Xiaochao Ma; Jeffrey R Idle; Kristopher W Krausz; Dun-Xian Tan; Leopoldo Ceraulo; Frank J Gonzalez
Journal:  J Pineal Res       Date:  2006-05       Impact factor: 13.007

2.  Subcellular distribution of melatonin receptors in human parotid glands.

Authors:  M Isola; J Ekström; M Diana; P Solinas; M Cossu; M A Lilliu; F Loy; R Isola
Journal:  J Anat       Date:  2013-09-03       Impact factor: 2.610

Review 3.  Clinical pharmacokinetics of melatonin: a systematic review.

Authors:  Nathja Groth Harpsøe; Lars Peter Holst Andersen; Ismail Gögenur; Jacob Rosenberg
Journal:  Eur J Clin Pharmacol       Date:  2015-05-27       Impact factor: 2.953

4.  Acute administration of melatonin at two opposite circadian stages does not change responses to gonadotropin releasing hormone, thyrotropin releasing hormone and ACTH in healthy adult males.

Authors:  P Paccotti; M Terzolo; M Torta; A Vignani; M Schena; A Piovesan; A Angeli
Journal:  J Endocrinol Invest       Date:  1987-10       Impact factor: 4.256

Review 5.  Melatonin and Multiple Sclerosis: From Plausible Neuropharmacological Mechanisms of Action to Experimental and Clinical Evidence.

Authors:  Mahshid Yeganeh Salehpour; Adriano Mollica; Saeideh Momtaz; Nima Sanadgol; Mohammad Hosein Farzaei
Journal:  Clin Drug Investig       Date:  2019-07       Impact factor: 2.859

6.  Pharmacokinetics of melatonin in man after intravenous infusion and bolus injection.

Authors:  C Mallo; R Zaĭdan; G Galy; E Vermeulen; J Brun; G Chazot; B Claustrat
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

7.  Diurnal rhythm of melatonin in bovine milk: pharmacokinetics of exogenous melatonin in lactating cows and goats.

Authors:  L Eriksson; M Valtonen; J T Laitinen; M Paananen; M Kaikkonen
Journal:  Acta Vet Scand       Date:  1998       Impact factor: 1.695

Review 8.  Melatonin: possible implications for the postoperative and critically ill patient.

Authors:  Richard S Bourne; Gary H Mills
Journal:  Intensive Care Med       Date:  2006-02-14       Impact factor: 17.440

9.  Melatonin: a novel indolamine in oral health and disease.

Authors:  V K Chava; K Sirisha
Journal:  Int J Dent       Date:  2012-07-31

Review 10.  Melatonin in perioperative medicine: Current perspective.

Authors:  Souvik Maitra; Dalim Kumar Baidya; Puneet Khanna
Journal:  Saudi J Anaesth       Date:  2013-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.